These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 20368223)

  • 21. Sensor and software use for the glycaemic management of insulin-treated type 1 and type 2 diabetes patients.
    Ajjan RA; Abougila K; Bellary S; Collier A; Franke B; Jude EB; Rayman G; Robinson A; Singh BM
    Diab Vasc Dis Res; 2016 May; 13(3):211-9. PubMed ID: 27000105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone.
    Raskin P; McGill J; Saad MF; Cappleman JM; Kaye W; Khutoryansky N; Hale PM;
    Diabet Med; 2004 Apr; 21(4):329-35. PubMed ID: 15049934
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.
    Wu D; Li L; Liu C
    Diabetes Obes Metab; 2014 Jan; 16(1):30-7. PubMed ID: 23803146
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial.
    Lund SS; Tarnow L; Frandsen M; Nielsen BB; Hansen BV; Pedersen O; Parving HH; Vaag AA
    BMJ; 2009 Nov; 339():b4324. PubMed ID: 19900993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study.
    Hassanein M; Abdallah K; Schweizer A
    Vasc Health Risk Manag; 2014; 10():319-26. PubMed ID: 24920915
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PREDICTIVE- a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort.
    Lüddeke HJ; Sreenan S; Aczel S; Maxeiner S; Yenigun M; Kozlovski P; Gydesen H; Dornhorst A;
    Diabetes Obes Metab; 2007 May; 9(3):428-34. PubMed ID: 17391171
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Challenges of maintaining research protocol fidelity in a clinical care setting: a qualitative study of the experiences and views of patients and staff participating in a randomized controlled trial.
    Lawton J; Jenkins N; Darbyshire JL; Holman RR; Farmer AJ; Hallowell N
    Trials; 2011 May; 12():108. PubMed ID: 21542916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gaps and barriers in the control of blood glucose in people with type 2 diabetes.
    Blonde L; Aschner P; Bailey C; Ji L; Leiter LA; Matthaei S;
    Diab Vasc Dis Res; 2017 May; 14(3):172-183. PubMed ID: 28467203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.
    Moretto TJ; Milton DR; Ridge TD; Macconell LA; Okerson T; Wolka AM; Brodows RG
    Clin Ther; 2008 Aug; 30(8):1448-60. PubMed ID: 18803987
    [TBL] [Abstract][Full Text] [Related]  

  • 30. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts).
    Raskin P; Matfin G; Schwartz SL; Chaykin L; Chu PL; Braceras R; Wynne A
    Diabetes Obes Metab; 2009 Jan; 11(1):27-32. PubMed ID: 17941873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment.
    Lukashevich V; Schweizer A; Foley JE; Dickinson S; Groop PH; Kothny W
    Vasc Health Risk Manag; 2013; 9():21-8. PubMed ID: 23378769
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Four decades of uncertainty: landmark trials in glycaemic control and cardiovascular outcome in type 2 diabetes.
    Matthews DR; Tsapas A
    Diab Vasc Dis Res; 2008 Sep; 5(3):216-8. PubMed ID: 18777497
    [No Abstract]   [Full Text] [Related]  

  • 36. Glycaemic control with liraglutide: the phase 3 trial programme.
    Raskin P; Mora PF
    Int J Clin Pract Suppl; 2010 Oct; (167):21-7. PubMed ID: 20887301
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Management of hyperglycaemia in type 2 diabetes: a patient-centered approach].
    Scheen AJ; Mathieu C
    Rev Med Liege; 2012 Dec; 67(12):623-31. PubMed ID: 23342872
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial.
    Davies M; Lavalle-González F; Storms F; Gomis R;
    Diabetes Obes Metab; 2008 May; 10(5):387-99. PubMed ID: 18355327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study).
    Garber AJ; Wahlen J; Wahl T; Bressler P; Braceras R; Allen E; Jain R
    Diabetes Obes Metab; 2006 Jan; 8(1):58-66. PubMed ID: 16367883
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of self-monitoring of blood glucose versus retrospective continuous glucose monitoring in improving glycaemic control in diabetic kidney disease patients.
    Yeoh E; Lim BK; Fun S; Tong J; Yeoh LY; Sum CF; Subramaniam T; Lim SC
    Nephrology (Carlton); 2018 Mar; 23(3):264-268. PubMed ID: 27933715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.